Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for PD-L1 Positive Metastatic Triple Negative Breast Cancer

Yale is conducting an open-label Phase Ib study evaluating two combination regimens—sacituzumab govitecan with nivolumab versus the same agent paired with fixed-dose nivolumab and relatlimab—in PD-L1 positive metastatic triple negative breast cancer patients who have received one prior line of chemotherapy with pembrolizumab.